The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Licensing of natural killer cells by host major histocompatibility complex class I molecules
Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y.-J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., et al. (2005) · Nature · doi:10.1038/nature03847 · Cited by 1,340
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1609337 · Cited by 1,296
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Human NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211
MHC class I molecules and kirs in human history, health and survival
Parham, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1570 · Cited by 1,203
“The latter has been described by Ruggeri et al.86 Alternatively, the effect observed by Cook et al.95 might be mediated by T cells: for example, by KIR2DS2+CD4+CD28–”
MethodNK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
“Mechanistically, NK cells can help to contain GvHD through distinct mechanisms including the killing of professional APCs and thereby controlling the proliferation and expansion of graft-specific T cell (314, 315).”
BackgroundSpaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008) · Blood · doi:10.1182/blood-2007-02-074997 · Cited by 1,146
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
Di Ianni, M., Falzetti, F., Carotti, A., Terenzi, A., Castellino, F., Bonifacio, E., Del Papa, B., Zei, T., Ostini, R. I., Cecchini, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311894 · Cited by 1,064
Self-citationTargeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006) · Blood · doi:10.1182/blood-2005-07-2775 · Cited by 1,067
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
“NK cells may participate in tumor-immune surveillance, in particular in leukemia (18), neuroblastoma (19), and gastrointestinal stromal tumors (20).”
Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
“Analternative approach thatprovides the immunotherapeutic benefits of allogeneic HCTwithout severe toxicity is the adoptive transfer of allogeneic lymphocytes that mediate the “graft versus leukemia” effect.”
BackgroundInfluentialAdvances in graft-versus-host disease biology and therapy
Blazar, B. R., Murphy, W. J., & Abedi, M. (2012) · Nature Reviews Immunology · doi:10.1038/nri3212 · Cited by 880
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Targeting natural killer cells and natural killer T cells in cancer
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., & Brossay, L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3174 · Cited by 850
“In these settings, recipients with acute myeloid leukaemia (AML) who received haplo-identical transplants from KIR ligand-mismatched donors had a marked reduction in relapse rates compared with an otherwise similar group of patients with AML who received transplants from KIR ligand-matched relative”
ResultLiu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
“NK cells do not cause GVHD,(8, 9) and thus open opportunities to produce an off-the-shelf product for immediate clinical use.”
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
New aspects of natural-killer-cell surveillance and therapy of cancer
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc928 · Cited by 752
“MHC class I expression has also been associated with protection against NK-cell-mediated lysis in patients that have received ALLOGENEIC bone-marrow transplantatio”
BackgroundShlomchik, W. D. (2007) · Nature Reviews Immunology · doi:10.1038/nri2000 · Cited by 735
Self-citationAversa, F., Terenzi, A., Tabilio, A., Falzetti, F., Carotti, A., Ballanti, S., Felicini, R., Falcinelli, F., Velardi, A., Ruggeri, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.117 · Cited by 707
Self-citationNatural killer cells and dendritic cells: rendezvous in abused tissues
Moretta, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri956 · Cited by 704
“Remarkably, this graft-versus-leukaemia (GVL) effect does not affect normal tissues that are usually attacked by the alloreactive T cells that mediate graft-versus-host disease (GVHD”
BackgroundThe Broad Spectrum of Human Natural Killer Cell Diversity
Freud, A. G., Mundy-Bosse, B. L., Yu, J., & Caligiuri, M. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.008 · Cited by 695
“This was first highlighted in a seminal study by Ruggeri et al. (2002) who observed that donor CD34+ progenitor cell-derived NK cells are critical to successful outcomes following T cell-depleted, MHC haploidentical, allogeneic, hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid…”
BackgroundNK cell-based cancer immunotherapy: from basic biology to clinical development
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01014-w · Cited by 689
“In order to avoid critical side effects, such as GVHD caused by alloreactive T cells [98] or a passenger lymphocyte syndrome caused by donor-derived B cells [99], purification is recommended for allogeneic NK cells before the expansion to restrict contaminating total T cells to less than 1–5 × 105/Kg.”
BackgroundInfluentialImai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
“By contrast, infusions of pure CD56 CD3 NK cells should not impose that risk.(12) Most clinical studies of the therapeutic effects of NK cells have been performed in an autologous setting and have yielded only moderately promising results.”
BackgroundRasmusson, I., Ringdén, O., Sundberg, B., & Le Blanc, K. (2003) · Transplantation · doi:10.1097/01.tp.0000082540.43730.80 · Cited by 663
“NK cells have been believed to be more important for GVL than GVHD (17, 18, 25).”
BackgroundActivation, coactivation, and costimulation of resting human natural killer cells
Bryceson, Y. T., March, M. E., Ljunggren, H., & Long, E. O. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00457.x · Cited by 650
“NK cells in T-celldepleted allogeneic hematopoietic grafts can mediate beneficial graft-versus-leukemia effects but not graft-versus-host disease (18).”
BackgroundNK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Natural-killer cells and dendritic cells: “l'union fait la force”
Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L., & Vivier, E. (2005) · Blood · doi:10.1182/blood-2005-03-1154 · Cited by 634
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Ruggeri, L., Mancusi, A., Capanni, M., Urbani, E., Carotti, A., Aloisi, T., Stern, M., Pende, D., Perruccio, K., Burchielli, E., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038687 · Cited by 616
“1 5/24 (20.8) 0/100 ND ND HLA-C 2 2 8/14 (57.1) 0/50 ND ND HLA-Bw4 3 12/40 (30) 0/40 ND ND HLA-Bw4 4 4/25 (16) 0/30 ND ND HLA-C 1 5 6/36 (16.7) 0/35 ND ND HLA-C 1 6 2/40 (5) 0/54 ND ND HLA-C 2 7 12/20 (60) 4/22 (18.2) 0/48 ND HLA-C 1 8 2/33 (6.1) 4/30 (13.3) 0/35 ND HLA-C 1 9 3/75 (4) 4/100 ( 4 ) 0/52 ND HLA-Bw4 10 1/…”
InfluentialSelf-citationSelf-tolerance of natural killer cells
Raulet, D. H., & Vance, R. E. (2006) · Nature Reviews Immunology · doi:10.1038/nri1863 · Cited by 608
“? And how do NK-cell tolerance mechanisms relate to recent findings showing that the inclusion of donor NK cells in human bone-marrow transplants given to HLA-mismatched individuals increases responses to host leukaemic cells and reduces the incidence of T-cell-mediated graft-versus-host diseas”
BackgroundExpansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
“Donor /recipient 80 (25) 144 (13) 92 (12) 52 (15)”
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
Maccario, R., Podestà, M., Moretta, A., Cometa, A. M., Comoli, P., Montagna, D., Daudt, L. E., Ibatici, A., Piaggio, G., Pozzi, S., et al. (2005) · PubMed · Cited by 580
Self-citationNK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Sivori, S., Vacca, P., Del Zotto, G., Munari, E., Mingari, M. C., & Moretta, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 555
Close encounters of different kinds: Dendritic cells and NK cells take centre stage
Degli-Esposti, M. A., & Smyth, M. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1549 · Cited by 554
“NK-cell alloreactivity that is generated in haploidentical, but KIR mismatched, transplants abolishes graft rejection and tumour relapse, and reduces graft-versus-host diseas”
BackgroundGiebel, S. (2003) · Blood · doi:10.1182/blood-2003-01-0091 · Cited by 549
“4 only residual leukemic cells, but also host T-cells and antigen-presenting cells, thereby favoring engraftment and preventing the development of acute GVHD [4].”
BackgroundMethodResultInfluentialFunctional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
Salih, H. R., Antropius, H., Gieseke, F., Lutz, S. Z., Kanz, L., Rammensee, H.-G., & Steinle, A. (2003) · Blood · doi:10.1182/blood-2003-01-0019 · Cited by 541
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H.-G., & Malmberg, K.-J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2073 · Cited by 543
“More recently, results from clinical haematopoietic SCT and adoptive NK-cell immunotherapy have indicated a role for NK cells in controlling and/or eradicating some types of human haematopoietic tumour”
BackgroundLoss of Mismatched HLA in Leukemia after Stem-Cell Transplantation
Vago, L., Perna, S. K., Zanussi, M., Mazzi, B., Barlassina, C., Stanghellini, M. T. L., Perrelli, N. F., Cosentino, C., Torri, F., Angius, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0811036 · Cited by 529
Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation
Welniak, L. A., Blazar, B. R., & Murphy, W. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141606 · Cited by 520
“Similar to HLA mismatches, the direction of KIR/KIR ligand incompatibility appears to impact outcomes in graft rejection, GVHD, and GVT in some (36) but not all (37, 38) clinical studies; the reasons for the differences are being intensively investigated.”
BackgroundHuman natural killer cell development and biology
Farag, S. S., & Caligiuri, M. A. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.10.001 · Cited by 506
Romagnani, C., Juelke, K., Falco, M., Morandi, B., D’Agostino, A., Costa, R., Ratto, G., Forte, G., Carrega, P., Lui, G., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.4947 · Cited by 494
“Our findings about KIR as inducible receptors might also have relevant implications for manipulating NK cell self-tolerance in clinical settings such as organ transplantation, in which KIR specificity has already been shown to be relevant for tumor rejection (26).”
BackgroundWhat does it take to make a natural killer?
Colucci, F., Caligiuri, M. A., & Di Santo, J. P. (2003) · Nature Reviews Immunology · doi:10.1038/nri1088 · Cited by 493
“These results can probably be explained on the basis of the conditioning regimen that is used and on the pattern of NK-cell recognitio”
BackgroundNatural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., & Caligiuri, M. A. (2002) · Blood · doi:10.1182/blood-2002-02-0350 · Cited by 491
Self-citationSpeiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 479
Ciceri, F., Bonini, C., Stanghellini, M. T. L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70074-9 · Cited by 488
Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma
Zhu, L., Kalimuthu, S., Gangadaran, P., Oh, J. M., Lee, H. W., Baek, S. H., Jeong, S. Y., Lee, S.-W., Lee, J., & Ahn, B.-C. (2017) · Theranostics · doi:10.7150/thno.18752 · Cited by 471
“Furthermore, NK cells have displayed excellent success in the treatment of metastatic breast cancer or hematological cancers such as acute myeloid leukemia [5, 6].”
BackgroundClassification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
“Conversely, in spite of promising preclinical findings [112-117], the adoptive transfer of purified natural killer (NK) cells to cancer patients has been associated with limited therapeutic activity [118-120].”
BackgroundHsu, K. C., Keever-Taylor, C. A., Wilton, A., Pinto, C., Heller, G., Arkun, K., O'Reilly, R. J., Horowitz, M. M., & Dupont, B. (2005) · Blood · doi:10.1182/blood-2004-12-4825 · Cited by 473
“54 The implication of the present study is twofold: (1) clonal distribution of KIR receptors may exist to give rise to KIR-driven alloreactive NK clones, and (2) these NK clones or their progenitors must also exist in the donor, who exhibits the same HLA genotype as the sibling recipient.”
BackgroundTreatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A., & Morgan, R. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1450 · Cited by 469
“The robust immunosuppressive nonmyeloablative conditioning in patients treated with allogeneic hematopoietic stem cell transplants (46,47) or in adoptive cell transfer procedures (5) may moderate or preclude the undesirable rejection of genetically modified lymphocytes expressing murine TCR genes.”
BackgroundMesenchymal stem cells: a new strategy for immunosuppression?
Uccelli, A., Pistoia, V., & Moretta, L. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.03.001 · Cited by 461
Uterine NK cells: active regulators at the maternal-fetal interface
Moffett, A., & Colucci, F. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68107 · Cited by 453
“Haploidentical BMT is now used as an alternative strategy when no MHC-matched donors for leukemia patients can be found; it is also beneficial in preventing leukemia relapse (80).”
BackgroundNiederwieser, D., Maris, M., Shizuru, J. A., Petersdorf, E., Hegenbart, U., Sandmaier, B. M., Maloney, D. G., Storer, B., Lange, T., Chauncey, T., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1340 · Cited by 457
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R., Liu, E., & Shpall, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 453
Hsu, K. C., Chida, S., Geraghty, D. E., & Dupont, B. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.19004.x · Cited by 443
Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Natural Killer Cell Education and Tolerance
Orr, M. T., & Lanier, L. L. (2010) · Cell · doi:10.1016/j.cell.2010.08.031 · Cited by 441
“Reciprocally, in HLAmismatched, T cell-depleted bone marrow grafts, positive outcomes correlate with lack of HLA ligands in the recipient for inhibitory KIRs on donor-derived NK cells (Miller et al., 2007; Ruggeri et al., 2002).”
Natural Killer Cells and Cancer
(2003) · Advances in Cancer Research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 438
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
“Tumor lysis by NK cells is limited by inhibitory killer immunoglobulin receptors (KIR) that mediate self tolerance by engaging major histocompatibility complex (MHC) class I antigens.1 In contrast, NK cells reconstituting after transplantation can overcome this MHC barrier by KIRligand mismatching to mediate a potent…”
BackgroundArai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-171926 · Cited by 434
Cooper, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.012 · Cited by 434
HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1
Venstrom, J. M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200503 · Cited by 429
Determinants of Antileukemia Effects of Allogeneic NK Cells
Leung, W., Iyengar, R., Turner, V., Lang, P., Bader, P., Conn, P., Niethammer, D., & Handgretinger, R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.644 · Cited by 425
“Prior investigations in adult patients have demonstrated the NK cell-mediated antileukemia effect toward AML, but not ALL (6, 7).”
BackgroundMethodResultInfluentialCD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
“Tumor immunity is not only T cell dependent; recently, a number of studies in leukemia (12), lymphoma (13), and gastrointestinal stromal tumors (14) revealed that NK cell activation and cytotoxicity influence patient outcome.”
BackgroundNatural killer cell biology: An update and future directions
Campbell, K. S., & Hasegawa, J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.006 · Cited by 416
“-host disease.(83-88) Increased survival was also reported for AML patients that received HLA-matched or mismatched HSC transplants containing KIR “B haplotypes”, which characteristically have more activating KIR.”
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Self-citationRomee, R., Cooley, S., Berrien-Elliott, M. M., Westervelt, P., Verneris, M. R., Wagner, J. E., Weisdorf, D. J., Blazar, B. R., Ustun, C., DeFor, T. E., et al. (2018) · Blood · doi:10.1182/blood-2017-12-823757 · Cited by 409
Killer immunoglobulin-like receptors
Moretta, L., & Moretta, A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.010 · Cited by 409
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
Self-citationA novel dendritic cell subset involved in tumor immunosurveillance
Taieb, J., Chaput, N., Ménard, C., Apetoh, L., Ullrich, E., Bonmort, M., Péquignot, M., Casares, N., Terme, M., Flament, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1356 · Cited by 405
“The innate component of IFN-γ production has been largely attributed to NK cells, which can lyse tumor cell”
BackgroundMartelli, M. F., Di Ianni, M., Ruggeri, L., Falzetti, F., Carotti, A., Terenzi, A., Pierini, A., Massei, M. S., Amico, L., Urbani, E., et al. (2014) · Blood · doi:10.1182/blood-2014-03-564401 · Cited by 399
“In the present series the T-cell dependent GvL effect was so powerful that it masked the anti-AML activity exerted by post-transplant generation of alloreactive donor-vs-recipient NK cell repertoires (37-39).”
BackgroundSelf-citationChiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
A Human CD34(+) Subset Resides in Lymph Nodes and Differentiates into CD56brightNatural Killer Cells
Freud, A. G., Becknell, B., Roychowdhury, S., Mao, H. C., Ferketich, A. K., Nuovo, G. J., Hughes, T. L., Marburger, T. B., Sung, J., Baiocchi, R. A., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.013 · Cited by 401
Graft-versus-leukemia reactions in allogeneic chimeras
Kolb, H.-J., Schmid, C., Barrett, A. J., & Schendel, D. J. (2004) · Blood · doi:10.1182/blood-2003-02-0342 · Cited by 397
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01205 · Cited by 398
“recipient NK cell alloreactivity, which was mainly resulted from KIR ligand incompatibility, could avoid relapse and graft rejection without GVHD in AML patients receiving HLA (Human leukocyte antigens) mismatch donor hematopoietic transplantation (87).”
BackgroundDendritic cell maturation by innate lymphocytes
Münz, C., Steinman, R. M., & Fujii, S.-I. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050810 · Cited by 393
“Finally, allogeneic hematopoetic stem cell transplantation mediates a graft-versus-leukemia effect, which has been ascribed to detection of mismatched HLA molecules by NK cells (35).”
BackgroundMolecules and mechanisms of the graft-versus-leukaemia effect
Bleakley, M., & Riddell, S. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1365 · Cited by 392
“gov/cancerinfo/pdq/treatment/adultALL/healthprofessional/">acute myelogenous leukaemia (AML) after T-cell-depleted HAPLO-IDENTICAL STEM-CELL TRANSPLANTATION in the subset of recipients that do not express the donor HLA class I molecules that are required to engage NK-cell inhibitory receptor”
BackgroundPerruccio, K., Tosti, A., Burchielli, E., Topini, F., Ruggeri, L., Carotti, A., Capanni, M., Urbani, E., Mancusi, A., Aversa, F., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1775 · Cited by 391
Self-citationPende, D., Falco, M., Vitale, M., Cantoni, C., Vitale, C., Munari, E., Bertaina, A., Moretta, F., Del Zotto, G., Pietra, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01179 · Cited by 389
“(197) reported a 5-year survival probability of ∼60% in adult AML patients in case of donor NK alloreactivity (KIR/KIR-L mismatch in graft vs.”
BackgroundLjungman, P., Bregni, M., Brune, M., Cornelissen, J., Witte, T. D., Dini, G., Einsele, H., Gaspar, H. B., Gratwohl, A., Passweg, J., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.141 · Cited by 388
Self-citationOlson, J. A., Leveson-Gower, D. B., Gill, S., Baker, J., Beilhack, A., & Negrin, R. S. (2010) · Blood · doi:10.1182/blood-2009-05-222190 · Cited by 384
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.